Time to Take the Lead – Practical Utilization of SGLT2 Inhibitors
Published: 18 December 2020
-
Views:
55 -
Likes:
7
-
Views:
55 -
Likes:
7
-
12m 25sPart 4 Case Discussion
-
13mPart 1 Introduction, and No Permission Needed – Cardiology Guidelines + Prescribing Practice Shelley Zieroth
Overview
This independent medical education symposium was supported by a grant from the Boehringer Ingelheim & Eli Lilly and Company alliance.
Learning objectives
- Understand current guidelines and utilisation of SGLT2i
- Describe the potential mechanism of benefit of SGLT2i
- Initiate and manage SGLT2i in appropriate patients
More from this programme
Part 1
Introduction, and No Permission Needed – Cardiology Guidelines + Prescribing Practice
Part 2
SGLT2i are Cardiovascular Drugs
1 session | |
SGLT2i are Cardiovascular Drugs | Watch now |
Part 3
Cardiologists Taking the Lead – How Can We Use SGLT2 Inhibitors in Our Clinical Practice?
Part 4
Case Discussion
1 session | |
Case Discussion | Watch now |
Part 5
A Follow-up Discussion to the ESC 2020 Session
Faculty Biographies